Table 2.
Clinical characteristics of each Ki67 group (<30% and >=30%).
| Characteristic | Ki67<30% | Ki67>=30% | P-value |
|---|---|---|---|
| (n = 51) | (n = 124) | ||
| No. % | No. % | ||
| Age | |||
| Median | 62.0 | 59.0 | |
| Range | 31.0-83.0 | 26.0-86.0 | |
| Age category | 0.289 | ||
| <65 | 32 (62.7) | 88 (71.0) | |
| ≥65 | 19 (37.3) | 36 (29.0) | |
| Sex | 0.300 | ||
| Female | 29 (56.9) | 82 (66.1) | |
| Male | 22 (43.1) | 42 (33.9) | |
| Primary site | 0.209 | ||
| Nasal cavity and sinuses | 22 (43.1) | 42 (33.9) | |
| Oral cavity | 4 (7.8) | 13 (10.5) | |
| Anorectal | 6 (11.8) | 23 (18.5) | |
| Genital tract* | 13 (25.5) | 34 (27.4) | |
| Urinary tract | 4 (7.8) | 2 (1.6) | |
| Esophagus | 2 (4.0) | 10 (8.1) | |
| Mutation status | 0.440 | ||
| BRAF | 3 (5.9) | 6 (4.8) | |
| c-KIT | 1 (2.0) | 7 (5.6) | |
| NRAS | 2 (3.9) | 14 (11.3) | |
| Wild type | 37 (72.5) | 79 (63.7) | |
| Unknown | 8 (15.7) | 18 (14.5) | |
| LDH level | 0.694 | ||
| ≤ULN | 46 (90.2) | 112 (90.3) | |
| >ULN | 4 (7.8) | 7 (5.7) | |
| Unknown | 1 (2.0) | 5 (4.0) | |
| Lymphatic metastasis | 0.086 | ||
| N | 46 (90.2) | 98 (79.0) | |
| Y | 5 (9.8) | 26 (21.0) | |
| Adjuvant therapy | 0.181 | ||
| TMZ-based Chemotherapy | 25 (49.0) | 75 (60.5) | |
| High dose IFN-α2b | 26 (51.0) | 49 (39.5) |
*Genital tract included the uterine cervix (2 cases in Ki67<30% group and 4 cases in Ki67>=30% group)_and vulvovaginal primary lesions (11 cases in Ki67<30% group and 30 cases in Ki67>=30% group).
LDH, lactate dehydrogenase; ULN, upper limit of normal; TMZ, temozolomide; IFN, interferon.